|
|
|
|
LEADER |
03742nam a2200517 4500 |
001 |
978-981-10-7691-6 |
003 |
DE-He213 |
005 |
20191023181854.0 |
007 |
cr nn 008mamaa |
008 |
180116s2018 si | s |||| 0|eng d |
020 |
|
|
|a 9789811076916
|9 978-981-10-7691-6
|
024 |
7 |
|
|a 10.1007/978-981-10-7691-6
|2 doi
|
040 |
|
|
|d GrThAP
|
050 |
|
4 |
|a RS400-431
|
072 |
|
7 |
|a PSB
|2 bicssc
|
072 |
|
7 |
|a SCI013020
|2 bisacsh
|
072 |
|
7 |
|a PSB
|2 thema
|
082 |
0 |
4 |
|a 615.19
|2 23
|
100 |
1 |
|
|a Tamamura, Hirokazu.
|e author.
|4 aut
|4 http://id.loc.gov/vocabulary/relators/aut
|
245 |
1 |
0 |
|a Mid-size Drugs Based on Peptides and Peptidomimetics
|h [electronic resource] :
|b A New Drug Category /
|c by Hirokazu Tamamura, Takuya Kobayakawa, Nami Ohashi.
|
250 |
|
|
|a 1st ed. 2018.
|
264 |
|
1 |
|a Singapore :
|b Springer Singapore :
|b Imprint: Springer,
|c 2018.
|
300 |
|
|
|a XVII, 100 p. 40 illus., 32 illus. in color.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a text file
|b PDF
|2 rda
|
490 |
1 |
|
|a SpringerBriefs in Pharmaceutical Science & Drug Development,
|x 1864-8118
|
505 |
0 |
|
|a 1. Introduction of Mid-Size Drugs and Peptidomimetics -- 2. Chloroalkene Dipeptide Isosteres as Peptidomimetics -- 3. Conformational-restricted Cyclic Peptides -- 4. Peptidomimetics that Mimic Secondary Structures of Peptides -- 5.Peptidomimetics that Mimic Tertiary Structures of Peptides -- 6. Conjugated Compounds Involving Peptides -- 7. Summary and Future Perspectives of Researches on Mid-Size Drugs.
|
520 |
|
|
|a This brief describes studies conducted by the authors on mid-size drugs utilizing peptides and peptidomimetics, and on the development of anti-HIV agents. Peptides are important biological molecules and have various physiological actions. Peptide-based drug discovery may help bring about the development of useful medicines that are highly safe and show potent pharmacological effects in small doses. Recently, it has been shown that there is an important drug-like space in the mid-sized region between low- and high-molecular-weight compounds. Thus, mid-size drugs such as peptide compounds are being focused on. To date, several peptidomimetics that mimic primary, secondary, and tertiary structures of peptides have been developed to maintain and improve biological activities and actions of peptides. In this book, the features and advantages of mid-size drugs are described in detail. In addition, the merits of utilizing peptidomimetics in the development of mid-size drugs are referred to. Understanding such peptide-derived mid-size drugs will lead to a comprehensive expansion of medicinal chemistry.
|
650 |
|
0 |
|a Medicinal chemistry.
|
650 |
|
0 |
|a Pharmaceutical technology.
|
650 |
|
0 |
|a Organic chemistry.
|
650 |
1 |
4 |
|a Medicinal Chemistry.
|0 http://scigraph.springernature.com/things/product-market-codes/C28000
|
650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|0 http://scigraph.springernature.com/things/product-market-codes/B21010
|
650 |
2 |
4 |
|a Organic Chemistry.
|0 http://scigraph.springernature.com/things/product-market-codes/C19007
|
700 |
1 |
|
|a Kobayakawa, Takuya.
|e author.
|4 aut
|4 http://id.loc.gov/vocabulary/relators/aut
|
700 |
1 |
|
|a Ohashi, Nami.
|e author.
|4 aut
|4 http://id.loc.gov/vocabulary/relators/aut
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|
776 |
0 |
8 |
|i Printed edition:
|z 9789811076909
|
776 |
0 |
8 |
|i Printed edition:
|z 9789811076923
|
830 |
|
0 |
|a SpringerBriefs in Pharmaceutical Science & Drug Development,
|x 1864-8118
|
856 |
4 |
0 |
|u https://doi.org/10.1007/978-981-10-7691-6
|z Full Text via HEAL-Link
|
912 |
|
|
|a ZDB-2-SME
|
950 |
|
|
|a Medicine (Springer-11650)
|